Showing results 1 to 20 of 57
next >
Issue Date | Title | Author(s) |
2018 | Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung | Lu, Shun; Li, Wei; Zhou, Caicun; Hu, Cheng-Ping; Qin, Shukui; Cheng, Gang; Feng, Jifeng; Wang, Jie; Cseh, Agnieszka; Peil, Barbara; Gibson, Neil; Ehrnrooth, Eva; Zhang, Li |
2018 | Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study | Li, Jin; Xu, Ruihua; Qin, Shukui; Liu, Tianshu; Pan, Hongming; Xu, Jianming; Bi, Feng; Lim, Robert; Zhang, Suzhan; Ba, Yi; Bai, Yuxian; Fan, Nanfeng; Tsuji, Akihito; Yeh, Kun-Huei; Ma, Brigette; Wei, Vivian; Shi, Dongmei; Magherini, Emmanuelle; Shen, Lin |
Dec-2024 | APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024 | Lau, George; Obi, Shuntaro; Zhou, Jian; Tateishi, Ryosuke; Qin, Shukui; Zhao, Haitao; Otsuka, Motoyuki; Ogasawara, Sadahisa; George, Jacob; Chow, Pierce K. H.; Cai, Jianqiang; Shiina, Shuichiro; Kato, Naoya; Yokosuka, Osamu; Oura, Kyoko; Yau, Thomas; Chan, Stephen L.; Kuang, Ming; Ueno, Yoshiyuki; Chen, Minshan; Cheng, Ann-Lii; Cheng, Gregory; Chuang, Wan-Long; Baatarkhuu, Oidov; Bi, Feng; Dan, Yock Young; Gani, Rino A.; Tanaka, Atsushi; Jafri, Wasim; Jia, Ji-Dong; Kao, Jia-Horng; Hasegawa, Kiyoshi; Lau, Patrick; Lee, Jeong Min; Liang, Jun; Liu, Zhenwen; Lu, Yinying; Pan, Hongming; Payawal, Diana A.; Rahman, Salimur; Seong, Jinsil; Shen, Feng; Shiha, Gamal; Song, Tianqiang; Sun, Hui-Chuan; Masaki, Tsutomu; Sirachainan, Ekaphop; Wei, Lai; Yang, Jin Mo; Sallano, Jose D.; Zhang, Yanqiao; Tanwandee, Tawesak; Dokmeci, Akadir; Zheng, Shu-sen; Fan, Jia; Fan, Sheung-Tat; Sarin, Shiv Kumar; Omata, Masao |
1-Jun-2022 | Apatinib versus placebo in patients with locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: Post hoc analyses from the REALITY randomized clinical trial. | Lin, Yan-Song; Qin, Shukui; Li, Zhiyong; Hui Yang; Wei Fu; Li, Shaohua; Chen, Wenxin; Gao, Zairong; Miao, Weibing; Xu, Huiqin; Qing Zhang; Zhao, Xinming; Bao, Jiandong; Li, Linfa; Yuan Ren; Lin, Chenghe; Jing, Shanghua; Ma, Qingjie; Jun Liang; Guang Chen |
2019 | Association between hand-foot skin reaction (HFSR) and survival benefit of fruquintinib in FRESCO trial. | Li, Jin; Qin, Shukui; Bai, Yuxian; Deng, Yanhong; Yang, Lei; Xu, Ruihua; Chen, Zhendong; Zhong, Haijun; Pan, Hongming; Guo, Weijian; Shu, Yongqian; Yuan, Ying; Xu, Jianming; Shen, Lin; Wang, Ning; Zhu, Chao; Fan, Songhua; Gong, Wei; Wang, Wei |
2015 | Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study | Qin, Shukui; Bi, Feng; Jin, Jie; Cheng, Ying; Guo, Jun; Ren, Xiubao; Huang, Yiran; Tarazi, Jamal; Tang, Jie; Chen, Connie; Kim, Sinil; Ye, Dingwei |
2015 | Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study) | Shen, Lin; Li, Jin; Xu, Jianming; Pan, Hongming; Dai, Guanghai; Qin, Shukui; Wang, Liwei; Wang, Jinwan; Yang, Zhenzhou; Shu, Yongqian; Xu, Ruihua; Chen, Lei; Liu, Yunpeng; Yu, Shiying; Bu, Lilian; Piao, Yongzhe |
Nov-2021 | Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition) | Sun, Hui-Chuan; Zhou, Jian; Wang, Zheng; Liu, Xiufeng; Xie, Qing; Jia, Weidong; Zhao, Ming; Bi, Xinyu; Li, Gong; Bai, Xueli; Ji, Yuan; Xu, Li; Zhu, Xiao-Dong; Bai, Dousheng; Chen, Yajin; Chen, Yongjun; Dai, Chaoliu; Guo, Rongping; Guo, Wenzhi; Hao, Chunyi; Huang, Tao; Huang, Zhiyong; Li, Deyu; Li, Gang; Li, Tao; Li, Xiangcheng; Liang, Xiao; Liu, Jingfeng; Liu, Fubao; Lu, Shichun; Lu, Zheng; Lv, Weifu; Mao, Yilei; Shao, Guoliang; Shi, Yinghong; Song, Tianqiang; Tan, Guang; Tang, Yunqiang; Tao, Kaishan; Wan, Chidan; Wang, Guangyi; Wang, Lu; Wang, Shunxiang; Wen, Tianfu; Xing, Baocai; Xiang, Bangde; Yan, Sheng; Yang, Dinghua; Yin, Guowen; Yin, Tao; Yin, Zhenyu; Yu, Zhengping; Zhang, Bixiang; Zhang, Jialin; Zhang, Shuijun; Zhang, Ti; Zhang, Yamin; Zhang, Yubao; Zhang, Aibin; Zhao, Haitao; Zhou, Ledu; Zhang, Wu; Zhu, Zhenyu; Qin, Shukui; Shen, Feng; Cai, Xiujun; Teng, Gaojun; Cai, Jianqiang; Chen, Minshan; Li, Qiang; Liu, Lianxin; Wang, Weilin; Liang, Tingbo; Dong, Jiahong; Chen, Xiaoping; Wang, Xuehao; Zheng, Shusen; Fan, Jia |
Jul-2023 | Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations | Wang, Jun; Zhang, Bicheng; Peng, Ling; Liu, Xiufeng; Sun, Jianguo; Su, Chunxia; Wang, Huijuan; Zhao, Zheng; Si, Lu; Duan, Jianchun; Zhang, Hongmei; Li, Mengxia; Zhu, Bo; Zhang, Li; Li, Jin; Guo, Jun; Luo, Rongcheng; Qiu, Wensheng; Ye, Dingwei; Chu, Qian; Cui, Jiuwei; Dong, Xiaorong; Fan, Yun; Gao, Quanli; Guo, Ye; He, Zhiyong; Li, Wenfeng; Lin, Gen; Liu, Lian; Liu, Yutao; Qin, Haifeng; Ren, Shengxiang; Ren, Xiubao; Wang, Yongsheng; Xue, Junli; Yang, Yunpeng; Yang, Zhenzhou; Yue, Lu; Zhan, Xianbao; Zhang, Junping; Ma, Jun; Qin, Shukui; Wang, Baocheng |
2013 | The Chinese subgroup from a randomized phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone as second-line treatment of HER2-amplified advanced gastric cancer (AGC) in Asian countries | Sun, Guo-ping; Sun, Yan; Xu, Rui-hua; Xu, Jian-Ming; Li, Jin; Wang, Jin-Wan; Qin, Shukui; Feng, Ji Feng; Ba, Yi; Shen, Lin; Bai, Yu-Xian; Sun, Yihong; Pan, Hongming; Cheng, Ying; Yu, Shiying; Zhong, Haijun; Bai, Li; Luo, Rongcheng; Kobayashi, Mikiro; Ohtsu, Atsushi |
2018 | Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China | Qin, Shukui; Kruger, Eliza; Tan, Seng Chuen; Cheng, Shuqun; Wang, Nanya; Liang, Jun |
2015 | Cross-sectional analysis of patients with non-mGC in China: An update of EVIDENCE gastric cancer registry study | Wang, Xin; Ji, Jiafu; Zheng, Zhichao; Zhang, Helong; Zhou, Weiping; Su, Wuyun; Luo, Qi; Guo, Qunyi; Li, Xiaoyi; Tang, Yong; Xu, Jian-Ming; Tao, Feng; Li, Wei; Li, Xiaoqin; Qin, Shukui; Yu, Eric Chi-Wang; Yang, Chen; Shen, Lin |
2015 | Cross-sectional analysis of patients with non-mGC in China: An update of EVIDENCE gastric cancer registry study | Wang, Xin; Ji, Jiafu; Zheng, Zhichao; Zhang, Helong; Zhou, Weiping; Su, Wuyun; Luo, Qi; Guo, Qunyi; Li, Xiaoyi; Tang, Yong; Xu, Jian-Ming; Tao, Feng; Li, Wei; Li, Xiaoqin; Qin, Shukui; Yu, Eric Chi-Wang; Yang, Chen; Shen, Lin |
20-May-2020 | Early carcinoembryonic antigen (CEA) dynamics to predict fruquintinib efficacy in FRESCO, a 3+line metastatic colorectal carcinoma (mCRC) phase III trial. | Bai, Yuxian; Qin, Shukui; Li, Jin; Deng, Yanhong; Yang, Lei; Xu, Rui-hua; Chen, Zhendong; Zhong, Haijun; Pan, Hongming; Guo, Weijian; Shu, Yongqian; Yuan, Ying; Xu, Jianming; Shen, Lin; Wang, Ning; Zhang, Bin; Zhang, Qiang; Fan, Songhua; Guo, Xiaojun; Peng, Mengye |
2018 | Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial | Li, Jin; Qin, Shukui; Xu, Rui-Hua; Shen, Lin; Xu, Jianming; Bai, Yuxian; Yang, Lei; Deng, Yanhong; Chen, Zhen-dong; Zhong, Haijun; Pan, Hongming; Guo, Weijian; Shu, Yongqian; Yuan, Ying; Zhou, Jianfeng; Xu, Nong; Liu, Tianshu; Ma, Dong; Wu, Changping; Cheng, Ying; Chen, Donghui; Li, Wei; Sun, Sanyuan; Yu, Zhuang; Cao, Peiguo; Chen, Haihui; Wang, Jiejun; Wang, Shubin; Wang, Hongbing; Fan, Songhua; Hua, Ye; Su, Weiguo |
2014 | Efficacy and Safety of the FOLFOX4 Regimen Versus Doxorubicin in Chinese Patients With Advanced Hepatocellular Carcinoma: A Subgroup Analysis of the EACH Study | Qin, Shukui; Cheng, Ying; Liang, Jun; Shen, Lin; Bai, Yuxian; Li, Jianfeng; Fan, Jia; Liang, Luian; Zhang, Yaqi; wu, Gang; Rau, Kun-Ming; Yang, Tsai-Shen; Jian, Zhixiang; Liang, Houjie; Sun, Yan |
20-May-2020 | Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency. | Shen, Lin; Li, Jian; Deng, Yanhong; Zhang, Weijie; Zhou, Aiping; Guo, Weijian; Yang, Jianwei; Yuan, Ying; Zhu, Liangjun; Qin, Shukui; Xiang, Silong; Lu, Haolan; Gong, John; Xu, Ting; Liu, David |
Jul-2021 | First-Line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis. | Shen, Lin; Bai, Yuxian; Lin, Xiaoyan; Li, Wei; Wang, Jufeng; Zhang, Xiaochun; Pan, Hongming; Bai, Chunmei; Bai, Li; Cheng, Ying; Zhang, Jingdong; Zhong, Haijun; Ba, Yi; Hu, Wenwei; Xu, Ruihua; Guo, Weijian; Qin, Shukui; Yang, Nong; Lu, Jianwei; Shitara, Kohei; Lei, Ming; Li, Mingshun; Bao, Nicole; Chen, Tian; Liu, Tianshu |
Oct-2022 | First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis | Liu, Tianshu; Bai, Yuxian; Lin, Xiaoyan; Li, Wei; Wang, Jufeng; Zhang, Xiaochun; Pan, Hongming; Bai, Chunmei; Bai, Li; Cheng, Ying; Zhang, Jingdong; Zhong, Haijun; Ba, Yi; Hu, Wenwei; Xu, Ruihua; Guo, Weijian; Qin, Shukui; Yang, Nong; Lu, Jianwei; Shitara, Kohei; Lei, Ming; Li, Mingshun; Bao, Nicole; Chen, Tian; Shen, Lin |
20-May-2021 | Four-year survival follow-up of toripalimab (JS001) as salvage therapy in Chinese melanoma patients. | Tang, Bixia; Chi, Zhihong; Chen, Yingbo; Liu, Xiufeng; Wu, Di; Chen, Jing; Song, Xin; Wang, Weifeng; Dong, Lihou; Song, Haifeng; Wu, Hai; Qin, Shukui; Guo, Jun; Zhang, Xiaoshi; Yao, Sheng; Feng, Hui |